ARA-290 is an 11-amino-acid peptide derived from the EPO helix B domain, utilized off-label primarily for neuropathic pain relief, tissue repair, and anti-inflammatory support. Users typically run daily doses ranging from 1 mg to 10 mg, with a community modal dose of 4 mg, while clinician-tier protocols suggest a range of 1 mg to 8 mg. Injection-site reactions are occasionally reported, though they remain infrequent. Readers should note that the evidence base for these exploratory indications is thinner than common discourse suggests, and the substance carries a 25% withdrawal rate across its registered trial program.
Data last updated
Evidence shape
ARA-290 possesses moderate clinical evidence, primarily supported by seven published human studies focused on treatment outcomes. While the research spans six distinct indications, including neuropathy of sarcoidosis, depression, and type 2 diabetes, the breadth remains thin with most conditions represented by only a single trial. The quality of this evidence is limited, as only one of the four registered trials is blinded with results, and the data reflects a 25% withdrawal rate across a small combined cohort of 64 participants.
Efficacy signal
Completed studies are present, but primary-endpoint pass/fail classification is not yet clean enough to score. These are the currently projected indication-level signals.
Neuropathy of Sarcoidosis
+106 µm^21 study · 1 completed
Depression
1 study · 1 completed
Diabetes Type 2
1 study
Diabetic Macular Oedema
1 study
2 completed study rows are present, but endpoint pass/fail classification is still pending.
Human evidence
Lower-tier support
Published literature
Standalone PubMed / Europe PMC publications matched to this peptide and deduped by identifier. Trial records and animal / in-vitro rows are surfaced above; these are the human-relevant papers behind them.
Source data
Clinical research side effects
Anecdotal side effects
price offers can be sorted by column · 14 out-of-stock offers not shown
How ARA-290 is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.
In research trials, ARA-290 was given subcutaneously at doses ranging from 1 mg to 8 mg daily, with a typical dose of 2 mg per day.
Clinician reports for ARA‑290 range from daily subcutaneous doses of 1 mg to 8 mg, while one source cites a weekly 2 mg subQ injection.
Most users who reported a schedule take 4 mg subQ daily; a smaller group dose every other day or three times weekly, with amounts ranging from 1 mg to 10 mg.